Minority patients and those with low income may be at greater risk of experiencing adverse outcomes in the management of asthma and eczema, according to study findings published in Advances in Therapy.
Although disparities have been reported regarding asthma and eczema outcomes across various populations, researchers highlight that little is known on how patients with these conditions perceive their medical care and burden of disease.
Notably, negative physical, emotional, and social impacts have been reported in prior surveys among patients with asthma and eczema, also known as atopic dermatitis, in which participants who identified as Black or Hispanic and those with low income were at significant risk.
“Both asthma and eczema are chronic conditions which often require lifelong treatment to achieve and maintain control, creating additional costs and emotional burden,” they added. “Individuals from racially/ethnically marginalized populations and those who report lower income also have reported lower rates of health insurance enrollment than those from non-marginalized groups, which impacts overall access to quality health care.”
The study authors conducted a 94-question online survey to evaluate the perceptions among the general patient population with asthma and/or eczema regarding disease and treatment burden and barriers to adequate care.
After recruiting 841 US patients with asthma (n = 554), eczema (n = 398), or both conditions (n = 111), participants 18 years or older provided survey responses between March 24, 2020, and April 6, 2020, and were stratified by racial/ethnic status and income level.
Of the study cohort, 76% were women, 50% identified as White (n = 421), 30% identified as Black (n = 252), and 11% identified as Hispanic (n = 95). A total of 99 patients reported low-income status (less than $15,000/year) and 713 were classified as having high income (at least $15,000/year).
“Asthma was reported by a higher percentage of participants identifying as Black or Hispanic than White participants (85% and 87% vs 48%, respectively),” noted researchers. “Whereas eczema was reported by a lower percentage of participants identifying as Black or Hispanic than White participants (21% and 19% vs 71%, respectively).”
In their findings, participants of low-income status reported greater prevalence of adverse management outcomes vs high-income counterparts:
- Prevalence of an asthma action plan was lower among participants with low income vs higher income counterparts (42% vs 53%).
- Prevalence of discussing asthma control with one’s health care provider was lower among participants with low income vs higher-income counterparts (54% vs 69%).
- More frequent eczema symptom burden among participants with low vs high income
- Fewer patients with eczema who had low income reported that they had not tried any eczema treatments vs those with high income (35% vs 15%)
Furthermore, more Black and Hispanic participants than White participants, as well as more participants with low income than higher income, endorsed health literacy as a barrier (eg, filling out official documents, understanding written materials).
Black and Hispanic participants were also more likely than White participants to have an emergency department visit (52% and 49% vs 31%, respectively) or hospitalization (31% and 39% vs 16%) for asthma within the last 12 months. Participants in all racial/ethnic and income-level groups reported that their asthma or eczema affected their lifestyle and daily activities.
“More effective and culturally informed communication and education strategies to improve health information uptake and shared decision-making are needed to reduce the burdens of disease and treatment in highly impacted populations,” concluded researchers.
Reference
Bukstein DA, Friedman A, Reyes EG, Hart M, Jones BL, Winders T. Impact of social determinants on the burden of asthma and eczema: results from a US patient survey. Adv Ther. Published online January 24, 2022. doi:10.1007/s12325-021-02021-0
Social Determinants May Influence Health Care Utilization, Symptom Burden in Patients With Asthma and Eczema
Minority patients and those with low income were more likely than White and high-income counterparts to report adverse outcomes in the management of asthma and eczema.
Minority patients and those with low income may be at greater risk of experiencing adverse outcomes in the management of asthma and eczema, according to study findings published in Advances in Therapy.
Although disparities have been reported regarding asthma and eczema outcomes across various populations, researchers highlight that little is known on how patients with these conditions perceive their medical care and burden of disease.
Notably, negative physical, emotional, and social impacts have been reported in prior surveys among patients with asthma and eczema, also known as atopic dermatitis, in which participants who identified as Black or Hispanic and those with low income were at significant risk.
“Both asthma and eczema are chronic conditions which often require lifelong treatment to achieve and maintain control, creating additional costs and emotional burden,” they added. “Individuals from racially/ethnically marginalized populations and those who report lower income also have reported lower rates of health insurance enrollment than those from non-marginalized groups, which impacts overall access to quality health care.”
The study authors conducted a 94-question online survey to evaluate the perceptions among the general patient population with asthma and/or eczema regarding disease and treatment burden and barriers to adequate care.
After recruiting 841 US patients with asthma (n = 554), eczema (n = 398), or both conditions (n = 111), participants 18 years or older provided survey responses between March 24, 2020, and April 6, 2020, and were stratified by racial/ethnic status and income level.
Of the study cohort, 76% were women, 50% identified as White (n = 421), 30% identified as Black (n = 252), and 11% identified as Hispanic (n = 95). A total of 99 patients reported low-income status (less than $15,000/year) and 713 were classified as having high income (at least $15,000/year).
“Asthma was reported by a higher percentage of participants identifying as Black or Hispanic than White participants (85% and 87% vs 48%, respectively),” noted researchers. “Whereas eczema was reported by a lower percentage of participants identifying as Black or Hispanic than White participants (21% and 19% vs 71%, respectively).”
In their findings, participants of low-income status reported greater prevalence of adverse management outcomes vs high-income counterparts:
Furthermore, more Black and Hispanic participants than White participants, as well as more participants with low income than higher income, endorsed health literacy as a barrier (eg, filling out official documents, understanding written materials).
Black and Hispanic participants were also more likely than White participants to have an emergency department visit (52% and 49% vs 31%, respectively) or hospitalization (31% and 39% vs 16%) for asthma within the last 12 months. Participants in all racial/ethnic and income-level groups reported that their asthma or eczema affected their lifestyle and daily activities.
“More effective and culturally informed communication and education strategies to improve health information uptake and shared decision-making are needed to reduce the burdens of disease and treatment in highly impacted populations,” concluded researchers.
Reference
Bukstein DA, Friedman A, Reyes EG, Hart M, Jones BL, Winders T. Impact of social determinants on the burden of asthma and eczema: results from a US patient survey. Adv Ther. Published online January 24, 2022. doi:10.1007/s12325-021-02021-0
Tarlatamab Receives Accelerated Approval for Extensive-Stage SCLC
May 17th 2024The FDA has approved tarlatamab, a novel bispecific T-cell engager, to treat patients with extensive-cell small cell lung cancer (SCLC).
Read More
Cancer Care Crisis: Illinois CancerCare Experts Discuss CMS Restrictions Impacting Rural Patients With Cancer
May 14th 2024On this episode of Managed Care Cast, experts from Illinois CancerCare discuss CMS regulations limiting the access of rural patients with cancer to medically integrated pharmacies.
Listen
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Sleep Quality in MS Impacted by Comorbidities, Study Finds
May 16th 2024This cross-sectional analysis demonstrates the impact that comorbidities in multiple sclerosis (MS) have on sleep quality in affected patients.
Read More
Most Insured Adults Still Have to Pay at Least Part of the Cost of GLP-1 Drugs
May 16th 2024Other findings from the latest Kaiser Family Foundation Health Tracking Poll shed light on public awareness, use, and opinions on Medicare coverage of glucagon-like peptide-1 (GLP-1) drugs.
Read More
Tarlatamab Receives Accelerated Approval for Extensive-Stage SCLC
May 17th 2024The FDA has approved tarlatamab, a novel bispecific T-cell engager, to treat patients with extensive-cell small cell lung cancer (SCLC).
Read More
Cancer Care Crisis: Illinois CancerCare Experts Discuss CMS Restrictions Impacting Rural Patients With Cancer
May 14th 2024On this episode of Managed Care Cast, experts from Illinois CancerCare discuss CMS regulations limiting the access of rural patients with cancer to medically integrated pharmacies.
Listen
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Sleep Quality in MS Impacted by Comorbidities, Study Finds
May 16th 2024This cross-sectional analysis demonstrates the impact that comorbidities in multiple sclerosis (MS) have on sleep quality in affected patients.
Read More
Most Insured Adults Still Have to Pay at Least Part of the Cost of GLP-1 Drugs
May 16th 2024Other findings from the latest Kaiser Family Foundation Health Tracking Poll shed light on public awareness, use, and opinions on Medicare coverage of glucagon-like peptide-1 (GLP-1) drugs.
Read More